| Literature DB >> 32723797 |
Roshan Kumar1, Helianthous Verma2, Nirjara Singhvi3, Utkarsh Sood4, Vipin Gupta5, Mona Singh5, Rashmi Kumari6, Princy Hira7, Shekhar Nagar3, Chandni Talwar3, Namita Nayyar8, Shailly Anand9, Charu Dogra Rawat2, Mansi Verma8, Ram Krishan Negi3, Yogendra Singh3, Rup Lal10.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) that started in Wuhan, China, in December 2019 has spread worldwide, emerging as a global pandemic. The severe respiratory pneumonia caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far claimed more than 0.38 million lives and has impacted human lives worldwide. However, as the novel SARS-CoV-2 virus displays high transmission rates, the underlying genomic severity is required to be fully understood. We studied the complete genomes of 95 SARS-CoV-2 strains from different geographical regions worldwide to uncover the pattern of the spread of the virus. We show that there is no direct transmission pattern of the virus among neighboring countries, suggesting that its spread is a result of travel of infected humans to different countries. We revealed unique single nucleotide polymorphisms (SNPs) in nonstructural protein 13 (nsp13), nsp14, nsp15, and nsp16 (ORF1b polyproteins) and in the S-protein within 10 viral isolates from the United States. These viral proteins are involved in RNA replication and binding with the human receptors, indicating that the viral variants that are circulating in the population of the United States are different from those circulating in the populations of other countries. In addition, we found an amino acid addition in nsp16 (mRNA cap-1 methyltransferase) of a U.S. isolate (GenBank accession no. MT188341.1) leading to a shift in the amino acid frame from position 2540 onward. Through comparative structural analysis of the wild-type and mutant proteins, we showed that this addition of a phenylalanine residue renders the protein in the mutant less stable, which might affect mRNA cap-1 methyltransferase function. We further analyzed the SARS-CoV-2-human interactome, which revealed that the interferon signaling pathway is targeted by orf1ab during infection and that it also interacts with NF-κB-repressing factor (NKRF), which is a potential regulator of interleukin-8 (IL-8). We propose that targeting this interaction may subsequently improve the health condition of COVID-19 patients. Our analysis also emphasized that SARS-CoV-2 manipulates spliceosome machinery during infection; hence, targeting splicing might affect viral replication. In conclusion, the replicative machinery of SARS-CoV-2 is targeting interferon and the notch signaling pathway along with spliceosome machinery to evade host challenges.IMPORTANCE The COVID-19 pandemic continues to storm the world, with over 6.5 million cases worldwide. The severity of the disease varies with the territories and is mainly influenced by population density and age factor. In this study, we analyzed the transmission pattern of 95 SARS-CoV-2 genomes isolated from 11 different countries. Our study also revealed several nonsynonymous mutations in ORF1b and S-proteins and the impact on their structural stability. Our analysis showed the manipulation of host system by viral proteins through SARS-CoV-2-human protein interactome, which can be useful to understand the impact of virus on human health.Entities:
Keywords: COVID-2019; SARS-CoV-2; viruses
Year: 2020 PMID: 32723797 PMCID: PMC7394360 DOI: 10.1128/mSystems.00505-20
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 6.496
General genomic attributes of SARS-CoV-2 strains
| Strain | Accession | Virus (SARS-CoV-2) | Country | Genome | GC% | Isolation source(s) | Date of isolation |
|---|---|---|---|---|---|---|---|
| 1 | Hu/DP/Kng/19-020 | Japan | 29,902 | 37.98 | Oronasopharynx | 10 February 2020 | |
| 2 | Hu/DP/Kng/19-027 | Japan | 29,902 | 38.02 | Oronasopharynx | 10 February 2020 | |
| 3 | TKYE6182_2020 | Japan | 29,903 | 37.97 | NA | January 2020 | |
| 4 | Wuhan seafood market pneumonia | China (Wuhan) | 29,872 | 38 | NA | 5 January 2020 | |
| 5 | WA8-UW5/human/2020/USA | United States | 29,732 | 37.97 | NA | 1 March 2020 | |
| 6 | Wuhan seafood market pneumonia | China (Wuhan) | 29,866 | 37.99 | NA | 26 December 2019 | |
| 7 | Wuhan-Hu-1 | China | 29,903 | 37.97 | NA | December 2019 | |
| 8 | 2019-nCoV_HKU-SZ-002a_2020 | China (Shenzhen) | 29,838 | 38.02 | Oronasopharynx | 10 January 2020 | |
| 9 | 2019-nCoV_HKU-SZ-005b_2020 | China | 29,891 | 37.98 | Oronasopharynx | 11 January 2020 | |
| 10 | 2019-nCoV/USA-WA1/2020 | United States | 29,882 | 38 | Oronasopharynx | 19 January 2020 | |
| 11 | 2019-nCoV WHU01 | China | 29,881 | 38 | NA | 2 January 2020 | |
| 12 | 2019-nCoV WHU02 | China | 29,881 | 38 | NA | 2 January 2020 | |
| 13 | 2019-nCoV/USA-IL1/2020 | United States | 29,882 | 37.99 | Lung, oronasopharynx | 21 January 2020 | |
| 14 | 2019-nCoV/USA-CA1/2020 | United States | 29,882 | 38 | Oronasopharynx | 23 December 2019 | |
| 15 | 2019-nCoV/USA-CA2/2020 | United States | 29,883 | 37.99 | Oronasopharynx | 22 January 2020 | |
| 16 | WIV02 | China | 29,825 | 38.02 | Lung | 30 December 2019 | |
| 17 | WIV04 | China | 29,891 | 37.99 | Lung | 30 December 2019 | |
| 18 | WIV05 | China | 29,852 | 38.02 | Lung | 30 December 2019 | |
| 19 | WIV06 | China | 29,854 | 38.03 | Lung | 30 December 2019 | |
| 20 | WIV07 | China | 29,857 | 38.02 | Lung | 30 December 2019 | |
| 21 | 2019-nCoV/USA-AZ1/2020 | United States | 29,882 | 37.99 | Feces | 22 January 2020 | |
| 22 | Australia/VIC01/2020 | Australia | 29,893 | 37.97 | NA | 25 January 2020 | |
| 23 | SARS-CoV-2/29/human/2020/IND | Kerala, India | 29,854 | 38.02 | Oronasopharynx | 27 January 2020 | |
| 24 | BetaCoV/Wuhan/IPBCAMS-WH-01/2019 | China | 29,899 | 37.98 | Lung | 23 December 2019 | |
| 25 | BetaCoV/Wuhan/IPBCAMS-WH-02/2019 | China | 29,889 | 38 | Lung | 30 December 2019 | |
| 26 | BetaCoV/Wuhan/IPBCAMS-WH-03/2019 | China | 29,899 | 37.98 | Lung | 30 December 2019 | |
| 27 | BetaCoV/Wuhan/IPBCAMS-WH-04/2019 | China | 29,890 | 37.99 | Lung | 30 December 2019 | |
| 28 | BetaCoV/Wuhan/IPBCAMS-WH-05/2020 | China | 29,883 | 37.99 | Lung | 1 January 2020 | |
| 29 | 2019-nCoV/USA-WA1-A12/2020 | United States | 29,882 | 38 | Oronasopharynx | 25 January 2020 | |
| 30 | 2019-nCoV/USA-WA1-F6/2020 | United States | 29,882 | 38 | Oronasopharynx | 25 January 2020 | |
| 31 | 2019-nCoV/USA-CA3/2020 | United States | 29,882 | 38 | Oronasopharynx | 29 January 2020 | |
| 32 | 2019-nCoV/USA-CA4/2020 | United States | 29,882 | 38 | Oronasopharynx | 29 January 2020 | |
| 33 | 2019-nCoV/USA-CA5/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 29 January 2020 | |
| 34 | HZ-1 | China | 29,833 | 38.02 | Lung, Oronasopharynx | 20 January 2020 | |
| 35 | 2019-nCoV/USA-WI1/2020 | United States | 29,879 | 38 | Oronasopharynx | 31 January 2020 | |
| 36 | 2019-nCoV/USA-MA1/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 29 January 2020 | |
| 37 | SNU01 | South Korea | 29,903 | 37.96 | NA | January 2020 | |
| 38 | 2019-nCoV/USA-IL2/2020 | United States | 29,882 | 38 | Lung, Oronasopharynx | 28 January 2020 | |
| 39 | 2019-nCoV/USA-CA6/2020 | United States | 29,858 | 38 | Oronasopharynx | 27 January 2020 | |
| 40 | SARS-CoV-2/Yunnan-01/human/ | China | 29,903 | 37.97 | Lung, Oronasopharynx | 17 January 2020 | |
| 41 | SARS-CoV-2/166/human/2020/IND | Kerala, India | 29,851 | 38.01 | Oronasopharynx | 31 January 2020 | |
| 42 | SARS-CoV-2/NM | Italy | 29,867 | 38.01 | Lung, Oronasopharynx | 30 January 2020 | |
| 43 | SARS-CoV-2/NTU01/2020/TWN | Taiwan | 29,870 | 38.01 | NA | 31 January 2020 | |
| 44 | SARS-CoV-2/NTU02/2020/TWN | Taiwan | 29,870 | 38.01 | NA | 5 February 2020 | |
| 45 | SARS0CoV-2/61-TW/human/2020/ NPL | Nepal | 29,811 | 38.02 | Oronasopharynx | 13 February 2020 | |
| 46 | SARS-CoV-2/01/human/2020/SWE | Sweden | 29,886 | 38 | NA | 7 February 2020 | |
| 47 | SARS-CoV-2/WH-09/human/2020/CHN | China | 29,860 | 38.02 | Oronasopharynx | 8 January 2020 | |
| 48 | 2019-nCoV/USA-CA7/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 6 February 2020 | |
| 49 | 2019-nCoV/USA-CA8/2020 | United States | 29,882 | 38 | Oronasopharynx | 10 February 2020 | |
| 50 | 2019-nCoV/USA-TX1/2020 | United States | 29,882 | 38 | Lung, Oronasopharynx | 11 February 2020 | |
| 51 | 2019-nCoV/USA-CA9/2020 | United States | 29,882 | 38 | Lung | 23 February 2020 | |
| 52 | SARS-CoV-2/SH01/human/2020/CHN | China | 29,945 | 37.91 | Oronasopharynx | 2 February 2020 | |
| 53 | SARS-CoV-2/IQTC01/human/2020/CHN | China | 29,891 | 38 | Oronasopharynx | 5 February 2020 | |
| 54 | SARS-CoV-2/IQTC02/human/2020/CHN | China | 29,882 | 37.99 | Lung | 29 January 2020 | |
| 55 | SARS-CoV-2/QT | China | 29,923 | 38.02 | Lung, Oronasopharynx | 27 January 2020 | |
| 56 | SARS-CoV-2/IQTC03/human/2020/CHN | China | 29,871 | 38 | Feces | 29 January 2020 | |
| 57 | SARS-CoV-2/SP02/human/2020/BRA | Brazil | 29,876 | 38 | Oronasopharynx | 28 February 2020 | |
| 58 | SARS-CoV-2/105/human/2020/CHN | China:Beijing | 29,903 | 37.97 | NA | 26 January 2020 | |
| 59 | SARS-CoV-2/231/human/2020/CHN | China:Beijing | 29,903 | 37.97 | NA | 28 January 2020 | |
| 60 | SARS-CoV-2/233/human/2020/CHN | China:Beijing | 29,903 | 37.97 | NA | 28 January 2020 | |
| 61 | SARS-CoV-2/235/human/2020/CHN | China:Beijing | 29,903 | 37.97 | NA | 28 January 2020 | |
| 62 | SARS-CoV-2/WA2/human/2020/USA | United States | 29,878 | 38 | Mid-nasal swab | 24 February 2020 | |
| 63 | 2019-nCoV/USA-CruiseA-7/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 17 February 2020 | |
| 64 | 2019-nCoV/USA-CruiseA-8/2020 | United States | 29,882 | 38 | Oronasopharynx | 17 February 2020 | |
| 65 | 2019-nCoV/USA-CruiseA-10/2020 | United States | 29,882 | 38 | Oronasopharynx | 17 February 2020 | |
| 66 | 2019-nCoV/USA-CruiseA-11/2020 | United States | 29,882 | 38 | Oronasopharynx | 17 February 2020 | |
| 67 | 2019-nCoV/USA-CruiseA-12/2020 | United States | 29,882 | 38 | Oronasopharynx | 20 February 2020 | |
| 68 | 2019-nCoV/USA-CruiseA-9/2020 | United States | 29,882 | 38 | Oronasopharynx | 17 February 2020 | |
| 69 | 2019-nCoV/USA-CruiseA-13/2020 | United States | 29,882 | 38 | Oronasopharynx | 20 February 2020 | |
| 70 | 2019-nCoV/USA-CruiseA-14/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 25 February 2020 | |
| 71 | 2019-nCoV/USA-CruiseA-15/2020 | United States | 29,882 | 38 | Oronasopharynx | 18 February 2020 | |
| 72 | 2019-nCoV/USA-CruiseA-16/2020 | United States | 29,882 | 38 | Oronasopharynx | 18 February 2020 | |
| 73 | 2019-nCoV/USA-CruiseA-17/2020 | United States | 29,882 | 38 | Oronasopharynx | 24 February 2020 | |
| 74 | 2019-nCoV/USA-CruiseA-18/2020 | United States | 29,867 | 38 | Oronasopharynx | 24 February 2020 | |
| 75 | 2019-nCoV/USA-CruiseA-1/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 17 February 2020 | |
| 76 | 2019-nCoV/USA-CruiseA-2/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 18 February 2020 | |
| 77 | 2019-nCoV/USA-CruiseA-3/2020 | United States | 29,882 | 38 | Oronasopharynx | 18 February 2020 | |
| 78 | 2019-nCoV/USA-CruiseA-4/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 21 February 2020 | |
| 79 | 2019-nCoV/USA-CruiseA-5/2020 | United States | 29,882 | 38 | Oronasopharynx | 21 February 2020 | |
| 80 | 2019-nCoV/USA-CruiseA-6/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 21 February 2020 | |
| 81 | SARS-CoV-2/WA3-UW1/human/ | United States | 29,903 | 37.95 | NA | 27 February 2020 | |
| 82 | SARS-CoV-2/WA4-UW2/human/ | United States | 29,897 | 37.97 | NA | 28 February 2020 | |
| 83 | SARS-CoV-2/WA6-UW3/human/ | United States | 29,903 | 37.97 | NA | 29 February 2020 | |
| 84 | SARS-CoV-2/WA7-UW4/human/ | United States | 29,903 | 37.97 | NA | 1 March 2020 | |
| 85 | Wuhan seafood market | China (Wuhan) | 29,732 | 37.96 | NA | 1 January 2020 | |
| 86 | 2019-nCoV/USA-CruiseA-19/2020 | United States | 29,882 | 38 | Oronasopharynx | 18 February 2020 | |
| 87 | 2019-nCoV/USA-CruiseA-21/2020 | United States | 29,880 | 38 | Oronasopharynx | 17 February 2020 | |
| 88 | 2019-nCoV/USA-CruiseA-22/2020 | United States | 29,882 | 38 | Oronasopharynx | 21 February 2020 | |
| 89 | 2019-nCoV/USA-CruiseA-23/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 18 February 2020 | |
| 90 | 2019-nCoV/USA-CruiseA-24/2020 | United States | 29,882 | 37.97 | Oronasopharynx | 17 February 2020 | |
| 91 | 2019-nCoV/USA-CruiseA-25/2020 | United States | 29,882 | 38 | Oronasopharynx | 17 February 2020 | |
| 92 | 2019-nCoV/USA-CruiseA-26/2020 | United States | 29,882 | 37.99 | Oronasopharynx | 24 February 2020 | |
| 93 | USA/MN3-MDH3/2020 | United States (MN) | 29,783 | 38.01 | Oronasopharynx | 7 March 2020 | |
| 94 | USA/MN2-MDH2/2020 | United States | 29,845 | 37.98 | Oronasopharynx | 9 March 2020 | |
| 95 | USA/MN1-MDH1/2020 | United States | 29,835 | 37.99 | Oronasopharynx | 5 March 2020 |
FIG 1(A) Core genome-based phylogenetic analysis of SARS-CoV-2 isolates using the maximum likelihood method based on the Tamura-Nei model. The analysis involved 95 SARS-CoV-2 sequences with a total of 28,451 nucleotide positions. Bootstrap values of more than 70% are shown on branches as blue dots with sizes corresponding to the bootstrap values. The colored circle represents the country of origin of each isolate. The two isolates from Wuhan are marked separately on the outer side of the ring. (B) The minimum spanning tree generated using maximum likelihood method and Tamura-Nei model showing the genetic relationships of SARS-CoV-2 isolates with their geographical distribution.
FIG 2(A) SNP-based phylogeny of SARS-CoV-2 isolates. Highly similar genomes of coronaviruses were taken as the input by Parsnp. Whole-genome alignments were made using libMUSCLE aligner and the annotated genome of MT121215 strain as the reference. Parsnp identifies the maximal unique matches (MUMs) among the query genomes provided in a single directory. As only the genomes corresponding to a specified MUM index (MUMI) distance threshold are recruited, option -c was used to force inclusion of all the strains. The output phylogeny based on single nucleotide polymorphisms was obtained following variant calling on core-genome alignment. (B) Multiple-sequence alignment of ORF1b protein showing amino acid substitutions at three positions: P1327L, Y1364C, and S2540F. The isolate USA/MN1-MDH1/2020 (MT188341) showed an amino acid addition leading to a change in an amino acid frame from position 2540 onward. (C and D) 2D and 3D structures for nsp16 in the wild-type strain (MT121215) and the mutant strain (MT188341) predicted using PDBsum and SWISS-MODEL. (E) Ramachandran plot of the predicted wild-type and mutant proteins, where the green region represents a most-favored region whereas the light green area denotes an allowed region. The white zone represents a generously allowed region.
Major mutations present in different isolates of SARS-CoV-2 at different locations
| Strain(s) with major mutation(s) | Protein | Position | Variant | Nucleotide |
|---|---|---|---|---|
| MT188341; MN985325; MT020881; MT020880; | NSP14 | 18060 | T | C |
| MT188341; MT163719; MT163718; MT163717; | NSP13 | 17747 | T | C |
| MT188341; MT163719; MT163718; MT163717; | NSP13 | 17858 | G | A |
| MT188341 | NSP13 | 16467 | G | A |
| Several strains under study | NSP3 | 6026 | C | T |
| MT039888 | NSP3 | 3518 | T | G |
| MT039888 | NSP3 | 17423 | G | A |
| MT163719 | NSP15 | 20281 | G | T |
| MT188339 | NSP16 | 21147 | C | T |
| MT188341 | S-protein | 23185 | T | C |
| MT163720 | S-protein | 23525 | T | C |
| MT188339 | S-protein | 22432 | T | C |
| MT159716 | S-protein | 22033 | A | C |
| MT050493 (Indian) | S-protein | 24351 | T | C |
NA, information not available.
FIG 3SARS-CoV-2–host interactome and its functional annotation. (A) SARS-CoV-2-host interaction map predicted using the IntAct database, showing human proteins interacting with 10 viral proteins. (B) Gene ontology (GO) analysis was performed for host proteins interacting with ORF1ab using the ClueGo Cytoscape app against database KEGG, the Gene Ontology—biological function database, and Reactome pathways. ClueGo parameters were set as follows: Go Term Fusion selected; P values of ≤0.05; GO tree interval, all levels; kappa score of 0.42.
FIG 4Estimation of purifying natural selection pressure in nine coding sequences of SARS-CoV-2. dN/dS values are plotted as a function of dS.